Fructose-1,6-bisphosphatase opposes renal carcinoma progression
Top Cited Papers
Open Access
- 20 July 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 513 (7517), 251-255
- https://doi.org/10.1038/nature13557
Abstract
Fructose-1,6-bisphosphatase is shown to be depleted in clear cell renal cell carcinoma (ccRCC) and inhibits ccRCC progression by antagonizing glycolytic flux in renal tubular epithelial cells and by restraining cell proliferation, glycolysis, and the pentose phosphate pathway in von Hippel–Lindau-protein-deficient ccRCC cells by blocking hypoxia-inducible factor function. von Hippel–Lindau mutations occur in the vast majority of clear cell renal cell carcinoma (ccRCC) tumours, and these mutations result in stabilization of hypoxia-inducible factors. But this is not sufficient to cause the typical metabolic alterations found in ccRCC, nor sufficient for tumour formation. This paper reports that fructose-1,6-bisphosphatase (FBP1) was uniformly depleted in all of more than six hundred ccRCC tumours examined. FBP1 is shown to inhibit renal carcinoma progression through two different mechanisms. First, the enzyme antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin, and this inhibits any potential 'Warburg effect'. Second, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in ccRCC cells deficient in the von Hippel–Lindau protein (pVHL) by blocking nuclear hypoxia-inducible factor function. Clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer1, is characterized by elevated glycogen levels and fat deposition2. These consistent metabolic alterations are associated with normoxic stabilization of hypoxia-inducible factors (HIFs)3 secondary to von Hippel–Lindau (VHL) mutations that occur in over 90% of ccRCC tumours4. However, kidney-specific VHL deletion in mice fails to elicit ccRCC-specific metabolic phenotypes and tumour formation5, suggesting that additional mechanisms are essential. Recent large-scale sequencing analyses revealed the loss of several chromatin remodelling enzymes in a subset of ccRCC (these included polybromo-1, SET domain containing 2 and BRCA1-associated protein-1, among others)6,7,8,9, indicating that epigenetic perturbations are probably important contributors to the natural history of this disease. Here we used an integrative approach comprising pan-metabolomic profiling and metabolic gene set analysis and determined that the gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1)10 is uniformly depleted in over six hundred ccRCC tumours examined. Notably, the human FBP1 locus resides on chromosome 9q22, the loss of which is associated with poor prognosis for ccRCC patients11. Our data further indicate that FBP1 inhibits ccRCC progression through two distinct mechanisms. First, FBP1 antagonizes glycolytic flux in renal tubular epithelial cells, the presumptive ccRCC cell of origin12, thereby inhibiting a potential Warburg effect13,14. Second, in pVHL (the protein encoded by the VHL gene)-deficient ccRCC cells, FBP1 restrains cell proliferation, glycolysis and the pentose phosphate pathway in a catalytic-activity-independent manner, by inhibiting nuclear HIF function via direct interaction with the HIF inhibitory domain. This unique dual function of the FBP1 protein explains its ubiquitous loss in ccRCC, distinguishing FBP1 from previously identified tumour suppressors that are not consistently mutated in all tumours6,7,15.This publication has 30 references indexed in Scilit:
- Integrated molecular analysis of clear-cell renal cell carcinomaNature Genetics, 2013
- Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivationOncogenesis, 2012
- Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomicsBiochemical Journal, 2012
- Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us?Cell, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011
- Functional genomics reveal that the serine synthesis pathway is essential in breast cancerNature, 2011
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- Hypoxia-Inducible Factors and the Response to Hypoxic StressMolecular Cell, 2010
- Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genesNature, 2010